| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Technology Officer & EVP | Chief Technology Officer | See Remarks +1 more
1 company
John G. Aunins last filed a Form 4 in January 2020, as Chief Technology Officer & EVP at MCRB. John G. Aunins's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 105,250 shares of MCRB. The MCRB filings lean toward selling, a net 211,340 shares.
John G. Aunins has 25 Form 4 filings on record from June 2015 to January 2020, all as Chief Technology Officer & EVP at Seres Therapeutics (MCRB), 2015–2020.
The 36 reported transactions were 19 open-market sales, 9 option or other derivative awards, 7 option exercises and 1 conversion.
Counted by filing, the open-market trades come to no purchases and 16 sales worth about $3.2M.
The largest open-market sale was 18,640 shares of MCRB at an average $31.94 on April 25, 2016, about $595K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2018 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sale+OE | 14,282 | $6.39 | $91,313.40 | -16.0% | |
| Nov 15, 2018 | MCRB Seres Therapeutics, Inc. | See Remarks | Sell | 14,279 | $8.26 | $117,911.70 | -13.8% | |
| Oct 15, 2018 | MCRB Seres Therapeutics, Inc. | See Remarks | Sell | 14,279 | $5.94 | $84,800.13 | -12.1% | |
| Sep 17, 2018 | MCRB Seres Therapeutics, Inc. | See Remarks | Sell | 42,837 | $7.64 | $327,344.65 | -26.6% | |
| Jul 15, 2018 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sell | 14,279 | $8.10 | $115,725.58 | -8.1% | |
| Jun 15, 2018 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sell | 14,279 | $8.57 | $122,325.34 | -7.7% | |
| Apr 25, 2018 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sell | 14,279 | $7.58 | $108,266.23 | -7.2% | |
| Jan 26, 2018 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE | 1,738 | $11.02 | $19,152.76 | -0.9% | |
| Dec 19, 2017 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sale+OE | 1,623 | $10.14 | $16,457.22 | -2.7% | |
| Aug 29, 2016 | MCRB Seres Therapeutics, Inc. | Chief Technology Officer & EVP | Sell | 9,390 | $10.87 | $102,069.30 | -4.7% |